Clinical trials: Stage III Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in patients with mHSPC who do not…
- Trial name
- REINFORCE (NCT07333066)
- Testing
- Apalutamide (Erleada™) 60 mg or 240 mg tablets, Docetaxel
- Where
- 56 sites in France, Germany and 3 more
- Volunteers
- 320 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy.
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT06650579
- Testing
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Emory University
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Metastatic Prostate Cancer
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.
- Trial name
- INTERVAL (NCT02730338)
- Testing
- High intensity aerobic and resistance training, Psychosocial support
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 866 people
- Sponsor
- Movember Foundation
Prostate Cancer
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses.
- Trial name
- NCT00363285
- Testing
- gonadotrophin releasing hormone, cyproterone acetate, quality-of-life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 900 people
- Sponsor
- St. Bartholomew's Hospital
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
This randomized phase II trial studies how well different doses of lycopene work in treating patients undergoing radical prostatectomy for prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00450749
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, lycopene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-Sensitive Prostate Cancer
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants…
- Trial name
- EvoPAR-PR01 (NCT06120491)
- Testing
- Saruparib, Abiraterone Acetate, Darolutamide
- Where
- 322 sites in United States, Australia and 22 more
- Volunteers
- 1,898 people
- Sponsor
- AstraZeneca
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
SMMART Adaptive Clinical Treatment (ACT) Trial
SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT05238831
- Testing
- Alectinib, Alpelisib, Anastrozole
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Castration-resistant Prostate Cancer
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the…
- Trial name
- NCT07365995
- Testing
- BNT324, Docetaxel, Prednisone/prednisolone
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 736 people
- Sponsor
- BioNTech SE
Prostate Cancer
Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer
Randomized phase III trial to compare treatment with or without adjuvant radiation therapy in men with stage III prostate cancer who have had radical prostatectomy and lymphadenectomy recently.
- Trial name
- NCT00394511
- Testing
- low-LET photon therapy
- Volunteers
- 408 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose
3-D conformal radiotherapy offers the opportunity to reach higher tumor doses with acceptable complication rates compared to conventional radiotherapy.
- Trial name
- NCT00692107
- Testing
- Gray
- Where
- 4 sites in Netherlands
- Volunteers
- 669 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Hormone-sensitive Prostate Cancer
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT).
- Trial name
- NCT03879122
- Testing
- Ipilimumab 5 MG/ML, Nivolumab 10 MG/ML, Docetaxel
- Where
- 30 sites in Spain
- Volunteers
- 135 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at…
- Trial name
- NCT03777982
- Testing
- Prednisone, Apalutamide, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Adenocarcinoma, Stage I Prostate Cancer
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02346253
- Testing
- Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Stanford University
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate…
- Trial name
- NCT00670046
- Testing
- valproic acid, standard of care follow-up
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins